Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening
Neuro-Oncology · 01.08.2026 · 28 (8) · 1904-1920
DOI: 10.1093/neuonc/noag093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 04.05.2026. Verfasst von Surender Surender und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Ka…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Glioma, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Else Kröner Fresenius Stiftung.
Abstract (Originalsprache)
Background
Glioblastoma harbors frequent alterations in the retinoblastoma pathway, providing a genetic rationale for therapeutic targeting with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The NOA-20 trial did not reveal a progression-free survival benefit of CDK4/6 inhibition plus radiation therapy in newly diagnosed, O6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma. In fact, CDK4/6 inhibitor monotherapy has not demonstrated efficacy in solid tumors. We aimed at discovering response modulators to CDK4/6 inhibition, paving the way for rational combination therapies.
Methods
We conducted genome-wide CRISPR-Cas9 screens in human glioma cell lines and stem-like cells (LN229, LN18, LNZ308, T98G, and GS-9) under CDK4/6 inhibition, employing knockout (Brunello library) and activation strategies (Calabrese library), followed by genetic and pharmacological validation of selected candidate genes in vitro and ex vivo (primary cultures) as well as the investigation of 1 functionally instructed combination therapy in vivo.
Results
Loss of AMBRA1 and gain of function of CCNE1 reduced sensitivity to CDK4/6 inhibition in glioma cells, whereas disruption of checkpoint kinase 1 (CHEK1) or FAM122A resulted in synthetic lethality in combination with CDK4/6 inhibition. AMBRA1-deficient glioma cells exhibited increased sensitivity to CHK1 inhibition, revealing a context-specific vulnerability. Combined inhibition of CHK1 and CDK4/6 led to synergistic antiglioma activity in vitro, ex vivo, and in vivo.
Conclusions
Our data identify AMBRA1, CCNE1, CHEK1, and FAM122A as potential molecular modifiers of CDK4/6 inhibition response in experimental glioma and provide a biological rationale for combinatorial targeting with CDK4/6 inhibition in glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.
- Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, Tübingen, Germany.
- German Cancer Consortium (DKTK), Partner Site Tübingen, A Partnership Between DKFZ and University Hospital Tübingen, Tübingen, Germany.
- Quantitative Biology Center, Eberhard Karls University Tübingen, Tübingen, Germany.
- Biomedical Data Science, Department of Computer Science, Eberhard Karls University Tübingen, Tübingen, Germany.
- Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen Stuttgart, Eberhard Karls University, Tübingen, Germany.
ORCID-Profile: Surender Surender, Lara Annina Haeusser, Foteini Tsiami, Nihal Olcay Dogan, Louise Maise, Sven Nahnsen, Daniel Josef Merk, Ghazaleh Tabatabai
Förderung
- Else Kröner Fresenius Stiftung
Zitieren
APA
Surender, S., Haeusser, L. A., Kuhlburger, L., Tsiami, F., Dogan, N. O., Maise, L., Nahnsen, S., Beck, S., Merk, D. J., & Tabatabai, G. (2026). Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening. Neuro-Oncology, 28(8), 1904-1920. https://doi.org/10.1093/neuonc/noag093
Vancouver
Surender S, Haeusser LA, Kuhlburger L, Tsiami F, Dogan NO, Maise L, et al. Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening. Neuro-Oncology. 2026;28(8):1904-1920. doi:10.1093/neuonc/noag093
BibTeX
@article{Surender2026,
author = {Surender, Surender and Haeusser, Lara Annina and Kuhlburger, Laurence and Tsiami, Foteini and Dogan, Nihal Olcay and Maise, Louise and Nahnsen, Sven and Beck, Susanne and Merk, Daniel Josef and Tabatabai, Ghazaleh},
title = {Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {8},
pages = {1904--1920},
doi = {10.1093/neuonc/noag093}
}
EUVIMED